Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia
Manabu Hayama,John Riches
DOI: https://doi.org/10.2147/ott.s443924
IF: 4
2024-03-09
OncoTargets and Therapy
Abstract:Manabu Hayama, John C Riches Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK Correspondence: John C Riches, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, United Kingdom, Tel +44 20 7882 3825, Email Chronic lymphocytic leukemia (CLL) is a monoclonal B-cell lymphoproliferative disease with a high annual incidence in Western countries. As B-cell receptor (BCR) signaling and intrinsic apoptotic resistance play critical roles in the development and survival of CLL cells, therapeutic approaches targeting these pathways have been extensively investigated to tackle this incurable disease. Over the last decade, several Phase 3 trials have confirmed the superior efficacy of covalent Bruton tyrosine kinase inhibitors (cBTKis) and venetoclax, a selective B-cell lymphoma 2 (BCL2) inhibitor, over chemoimmunotherapy. This has been demonstrated in both the treatment-naïve and relapsed/refractory (RR) settings and includes patients with high-risk molecular features. However, these drugs are not curative, with patients continuing to relapse after treatment with both cBTKis and BCL2is, and the optimal treatment strategy for these patients has not been defined. Several novel agents with distinct mechanisms have recently been developed for CLL which have demonstrated efficacy in patients who have previously received cBTKis and BCL2i. In particular, novel BCR-signaling targeting agents have shown promising efficacy in early-phase clinical trials for RR-CLL. Furthermore, cancer immunotherapies such as bispecific antibodies and chimeric antigen receptor T-cells have also shown anti-tumor activity in patients with heavily pretreated RR-CLL. Personalised approaches with these novel agents and combination strategies based on the understanding of resistance mechanisms have the potential to overcome the clinical challenge of what to do next for a patient who has already had a cBTKi and venetoclax. Keywords: CLL, BTK inhibitor, BCL2 inhibitor, bispecific antibody, CAR-T cell therapy Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) is an indolent hematological malignancy, characterized by the clonal proliferation and accumulation of functionally incompetent B cells in the blood, bone marrow, lymph nodes and spleen. 1 CLL and SLL are considered to be the same disease with different manifestations. The clinical presentation of CLL is primarily that of a peripheral lymphocytosis, whereas patients with SLL only manifest lymphadenopathy and organomegaly. 2 CLL is the most common adult leukemia in Western countries. 3 Traditional chemotherapeutic agents such as bendamustine, chlorambucil, fludarabine and cyclophosphamide used in combination with anti-CD20 monoclonal antibodies (mAbs) could induce long-term remissions, with these chemoimmunotherapy (CIT) regimens representing the standard treatment options for CLL until the advent of targeted therapies. 4–6 As B-cell receptor (BCR) signaling mediates the development and differentiation of normal B cells and plays a crucial role in tumorigenesis of B-cell malignancies including CLL, therapeutic approaches targeting key molecules in the BCR-signaling pathways such as Bruton tyrosine kinase (BTK) and phosphatidylinositol-3-kinase (PI3K) were investigated. 7 In 2014, ibrutinib, the first-in-class covalent BTK inhibitor (cBTKi) was approved by the US Food and Drug Administration (FDA) for the treatment of relapsed/refractory (RR) CLL based on its remarkable clinical efficacy. 8 Following this, more selective next-generation cBTKis such as acalabrutinib and zanubrutinib were developed to improve the efficacy and safety of ibrutinib. 9 Several phase 3 trials confirmed the superior efficacy of these cBTKis as monotherapy or in combination with an anti-CD20 mAb to CITs in the frontline and subsequent treatment settings. 10–13 Another important treatment target is an anti-apoptotic protein B-cell lymphoma 2 (BCL2), which is overexpressed in CLL cells. 14 Venetoclax, an oral selective BCL2 inhibitor (BCL2i), in combination with an anti-CD20 mAb also showed significant improvements in clinical outcomes compared to CITs. 15,16 These targeted therapies have dramatically transformed the treatment landscape of CLL and long-term survival can be achieved for many patients even those with high-risk features such as TP53 dysruption and complex karyotypes. However, CLL remains an incurable disease and patients experience disease progression after clinical responses to cBTKis and venetoclax. In this situation, they have limited treatment options with poor clinical outcomes, which highlights a significant unmet medical need. 17 Based -Abstract Truncated-
oncology,biotechnology & applied microbiology